CoBra

Cooperative Brachytherapy
Priority Axis
Technological and Social InnovationSpecific objective
Technological Innovation
Lead partner
University of Lille: Sciences and TechnologiesContact
Date de début
01/01/2018Date de fin
30/09/2022Project budget
3 801 252 €ERDF amount
2 280 751 €ERDF rate
60%À propos
Common challenge
The common challenge concerned by CoBra project is related to the cancer control plan.
The CoBra project is interested on technological innovation for diagnosis and treatment of localised cancers able to enhance the quality of life for patient and reduce the cancer mortality.
Overall objective
Main outputs
Cross border approach
Main Achievements
During 2020, the CoBra project progressed very well in terms of achieving the goals of developing and integrating the first working prototype of the MR-robot for the biopsy and brachytherapy, with respect to the initial work plan. Thanks to the video conferencing on regular basis (biweekly Technical Meetings among consortium and parter-to-partner weekly meetings) and to the eagerness of the consortium members to complete the tasks according to planning, it has been possible to overcome the pandemic-related limitations and built the first robot prototype that has been assembled, tested successfully with the bio-inspired phantom (first prototype) in the MRI environment.
Compared to the 2019, where the different parts of the integrated solution have been in early development stages, during 2020 the project has been able to attain such objectives as:
- The advanced version of MR- compatible steerable needle module for brachytherapy developed by PP3 in collaboration with LP1 (in the form of regular technical meetings to frame the integration of the module into the robot).
- The MR-compatible biopsy module with the storage system developed and accomplished by PP6 in collaboration with LP1 (in the form of regular technical meetings to frame the integration of the module into the robot).
- MR-compatible seed loader has been developed by the LP1.
The 3D simulation platform has been developed and is currently in progress of integration with the upgraded trajectory planning algorythm and the bio-inspired pahntom for tests and validation of concept at this stage.
The study on socio-economic impacts of the technology innovation has been also conducted and has shown promising results for the CoBra robotic solution to enhance coherence in the diagnosis and treatment of prostate cancers.
The joint intellectual property strategy has been elaborated and companies for technology transfer have been in contact with the project.
CoBra has been involved also in dissemination events like MedFIT 2020 and various workshops notwithstanding the limitations caused by sanitary crisis.
Overall progress of the project has been also presented during the virtual Annual Contact with JS of Interreg 2 Seas in October 2020 which represented positive results and progress achieved thanks to the active and efficient collaboration within the consortium.